Astellas Pharma (OTCMKTS:ALPMY - Get Free Report) posted its quarterly earnings data on Wednesday. The company reported $0.35 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.41 by ($0.06), Zacks reports. Astellas Pharma had a return on equity of 25.79% and a net margin of 16.01%.
Astellas Pharma Trading Down 0.1%
Shares of OTCMKTS ALPMY traded down $0.01 during midday trading on Wednesday, reaching $16.11. 72,842 shares of the stock were exchanged, compared to its average volume of 148,332. The business has a 50-day simple moving average of $15.03 and a two-hundred day simple moving average of $14.73. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.20 and a quick ratio of 0.93. The company has a market capitalization of $29.15 billion, a price-to-earnings ratio of 12.26 and a beta of 0.06. Astellas Pharma has a 12 month low of $10.64 and a 12 month high of $17.35.
Wall Street Analysts Forecast Growth
Separately, Zacks Research lowered shares of Astellas Pharma from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, Astellas Pharma presently has a consensus rating of "Moderate Buy".
Check Out Our Latest Research Report on Astellas Pharma
Astellas Pharma Company Profile
(
Get Free Report)
Astellas Pharma Inc is a Japan-based pharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines. Its research and commercial activities focus on areas including oncology, urology, immunology, neuroscience, ophthalmology and rare diseases. The company serves patients and healthcare providers in Japan, North America, Europe and other international markets.
Astellas' portfolio includes medicines such as Xtandi (enzalutamide) for certain prostate cancers, Xospata (gilteritinib) for acute myeloid leukemia, Prograf (tacrolimus) for transplant-related immunosuppression, and Myrbetri (mirabegron) for overactive bladder.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Astellas Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astellas Pharma wasn't on the list.
While Astellas Pharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
